School of Medicine and Health Sciences Poster Presentations

Title

Antihypertensive treatment to lower cardiovascular risk among post-menopausal women on estrogen replacement therapy

Document Type

Poster

Abstract Category

Women/Child Health

Keywords

postmenopausal women, Hypertension, estrogen, hormone replacement

Publication Date

Spring 5-1-2019

Abstract

The project investigates the optimal antihypertensive therapy for elderly women on hormone replacement therapy. Hypertension is a major public health challenge in the United States. The Antihypertensive and Lipid Lowering Treatment to Prevent Heart Attack (ALLHAT) trial established that among available hypertensive therapies, hydrochlorothiazide (HCTZ) diuretics are superior to calcium-channel blockers and angiotensin-converting enzyme inhibitors in preventing 1 or more major forms of cardiovascular disease (CVD). Postmenopausal women on hormonal replacement therapy are generally at increased cardiovascular risks. There have been several studies that suggest lower of tolerance of HCTZ compared to other hypertensive medications in this population. The goal of the study is to give healthcare providers with more liberty to select initial anti-hypertensive medication for postmenopausal women on estrogen replacement therapy, taking into account individual patient's side effect profile and other comorbidities.

Open Access

1

Comments

Presented at Research Days 2019.

This document is currently not available here.

Share

COinS
 

Antihypertensive treatment to lower cardiovascular risk among post-menopausal women on estrogen replacement therapy

The project investigates the optimal antihypertensive therapy for elderly women on hormone replacement therapy. Hypertension is a major public health challenge in the United States. The Antihypertensive and Lipid Lowering Treatment to Prevent Heart Attack (ALLHAT) trial established that among available hypertensive therapies, hydrochlorothiazide (HCTZ) diuretics are superior to calcium-channel blockers and angiotensin-converting enzyme inhibitors in preventing 1 or more major forms of cardiovascular disease (CVD). Postmenopausal women on hormonal replacement therapy are generally at increased cardiovascular risks. There have been several studies that suggest lower of tolerance of HCTZ compared to other hypertensive medications in this population. The goal of the study is to give healthcare providers with more liberty to select initial anti-hypertensive medication for postmenopausal women on estrogen replacement therapy, taking into account individual patient's side effect profile and other comorbidities.